JP2023512084A5 - - Google Patents
Info
- Publication number
- JP2023512084A5 JP2023512084A5 JP2022546426A JP2022546426A JP2023512084A5 JP 2023512084 A5 JP2023512084 A5 JP 2023512084A5 JP 2022546426 A JP2022546426 A JP 2022546426A JP 2022546426 A JP2022546426 A JP 2022546426A JP 2023512084 A5 JP2023512084 A5 JP 2023512084A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition according
- subject
- drug conjugate
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968808P | 2020-01-31 | 2020-01-31 | |
| US62/968,808 | 2020-01-31 | ||
| PCT/US2021/015685 WO2021155129A1 (en) | 2020-01-31 | 2021-01-29 | Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512084A JP2023512084A (ja) | 2023-03-23 |
| JP2023512084A5 true JP2023512084A5 (https=) | 2024-02-02 |
Family
ID=74672470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546426A Pending JP2023512084A (ja) | 2020-01-31 | 2021-01-29 | 抗ｃｄ３０抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230090868A1 (https=) |
| EP (1) | EP4096713A1 (https=) |
| JP (1) | JP2023512084A (https=) |
| KR (1) | KR20220146488A (https=) |
| CN (1) | CN115697400A (https=) |
| AU (1) | AU2021212193A1 (https=) |
| CA (1) | CA3169661A1 (https=) |
| IL (1) | IL295202A (https=) |
| MX (1) | MX2022009389A (https=) |
| WO (1) | WO2021155129A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024183817A1 (zh) * | 2023-03-09 | 2024-09-12 | 浙江特瑞思药业股份有限公司 | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| EA020696B1 (ru) * | 2007-10-12 | 2015-01-30 | Сиэтл Дженетикс, Инк. | Способ лечения лимфомы ходжкина с использованием комбинации гемцитабина и конъюгата антитела против cd30 с ауристатином |
| WO2010081004A1 (en) | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| IL238323B2 (en) * | 2012-10-30 | 2023-11-01 | Esperance Pharmaceuticals Inc | Antibody/drug conjugates and methods of use |
| KR102331013B1 (ko) * | 2016-01-14 | 2021-11-26 | 강푸 바이오파마슈티칼즈 리미티드 | 퀴나졸리논 유도체, 이의 제조방법, 약학 조성물 및 적용 |
| WO2018167847A1 (ja) * | 2017-03-14 | 2018-09-20 | 株式会社島津製作所 | モノクローナル抗体の同時定量方法 |
| WO2019146773A1 (ja) * | 2018-01-25 | 2019-08-01 | 株式会社フジモト・コーポレーション | チオフェン誘導体およびその用途 |
| CN111699005A (zh) * | 2018-02-12 | 2020-09-22 | 四十七公司 | 使用抗cd47抗体和抗cd20抗体的抗癌方案 |
-
2021
- 2021-01-29 EP EP21707120.8A patent/EP4096713A1/en active Pending
- 2021-01-29 IL IL295202A patent/IL295202A/en unknown
- 2021-01-29 CA CA3169661A patent/CA3169661A1/en active Pending
- 2021-01-29 WO PCT/US2021/015685 patent/WO2021155129A1/en not_active Ceased
- 2021-01-29 KR KR1020227030144A patent/KR20220146488A/ko not_active Withdrawn
- 2021-01-29 US US17/795,829 patent/US20230090868A1/en active Pending
- 2021-01-29 JP JP2022546426A patent/JP2023512084A/ja active Pending
- 2021-01-29 AU AU2021212193A patent/AU2021212193A1/en active Pending
- 2021-01-29 MX MX2022009389A patent/MX2022009389A/es unknown
- 2021-01-29 CN CN202180024561.3A patent/CN115697400A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113924318A (zh) | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 | |
| JP2011507932A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| RU2010130977A (ru) | Иммуноконъюгаты, направленные на cd138, и их применение | |
| IL274122B2 (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2021501776A5 (https=) | ||
| US20240307541A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
| JP2022513386A5 (https=) | ||
| JP2023508496A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2021523158A5 (https=) | ||
| US20220313822A1 (en) | Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody | |
| JP2022541591A5 (https=) | ||
| JP2021534165A5 (https=) | ||
| JP2023500697A5 (https=) | ||
| JP2025501978A5 (https=) | ||
| JP2023500888A5 (https=) | ||
| JP2023520771A5 (https=) | ||
| JP2026001086A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| US20230190949A1 (en) | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates | |
| JP2022502508A5 (https=) | ||
| JP2021501800A5 (https=) | ||
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| IL315350A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |